Bluechiip Ltd (ASX:BCT) provide the AGM Presentation for 2019.
Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at http://www.bluechiip.com
Bluechiip Limited (ASX:BCT) is pleased to report the successful completion of the recently announced Share Purchase Plan (SPP), which raised approximately $4.5 million.
Bluechiip Ltd (ASX:BCT) is offering Eligible Shareholders the opportunity to participate in the Bluechiip Share Purchase Plan (SPP).
Bluechiip Limited (ASX:BCT) is pleased to confirm that, further to its ASX Release dated 24 October 2019, the Company has now completed the institutional share placement (Placement) of new fully paid ordinary shares.
Bluechiip Limited (ASX:BCT), a leader in the development of sample-tracking technology for harsh environments, today announced it has successfully raised $4.6 million via a placement to institutional, sophisticated and professional investors.
Bluechiip Ltd (ASX:BCT) announce the October 2019 Investor Presentation
Bluechiip Ltd (BCT.AX) Open Briefing interview with MD Andrew McLellan where Andrew discusses the last quarter of revenue and new developments.
Bluechiip Ltd (ASX:BCT) recorded net sales revenue of $103k and sales receipts of $441k for the quarter, attributable to the sales of chips, readers, software and services.
Bluechiip Ltd's (ASX:BCT) technology wirelessly tracks the identification and temperature of valuable samples such as tissue, blood, serum and plasma which are stored in vials and bags in harsh environments like liquid nitrogen.
Bluechiip Ltd (ASX:BCT) Managing Director, Andrew McLellan on Bluechiip deliveries, operations and opportunities for June Quarter on Open Briefing.